🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against superbug strains of the infection, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are increasing worldwide, with figures suggesting in excess of 82 million infections annually. Particularly high rates are seen in the African continent and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices presently on offer.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

Zoliflodacin, also known as a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in the same week. This drug, which is also used to treat UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This approval marks a major breakthrough in the management of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Data and Worldwide Availability

According to findings detailed in a major medical journal, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which combines a dual-drug approach. The trial enrolled nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to make available and distribute the drug in a wide range of developing nations.

Clinicians treating patients have voiced positive views. The availability of a one-pill regimen such as this is seen as a "critical tool" for gonorrhoea control. This is deemed essential to lessen the impact of the infection for people and to stop the proliferation of untreatable gonorrhoea worldwide.